Published in final edited form as:

Eur J Inorg Chem. 2018 January 10; 2018(1): 7–15. doi:10.1002/ejic.201700776.

Cu(II) binding to various forms of amyloid- β peptides. Are they friends or foes?

Valentina Borghesani^{a,b}, Bruno Alies^c, and Christelle Hureau^{a,b,*}

^aCNRS, LCC (Laboratoire de Chimie de Coordination), 205 route de Narbonne, BP 44099 31077 Toulouse Cedex 4, France

^bUniversity of Toulouse, UPS, INPT, 31077 Toulouse Cedex 4, France

Abstract

In the present micro-review, we describe the Cu(II) binding to several forms of amyloid- β peptides, the peptides involved in Alzheimer's disease. It has indeed been shown that in addition to the "full-length" peptide originating from the precursor protein after cleavage at position 1, several other shorter peptides do exist in large proportion and may be involved in the disease as well. Cu(II) binding to amyloid- β peptides is one of the key interactions that impact both the aggregating properties of the amyloid peptides and the Reactive Oxygen Species (ROS) production, two events linked to the etiology of the disease. Binding sites and affinity are described in correlation with Cu(II) induced ROS formation and Cu(II) altered aggregation, for amyloid peptides starting at position 1, 3, 4, 11 and for the corresponding pyroglutamate forms when they could be obtained (i.e. for peptides cleaved at positions 3 and 11). It appears that the current paradigm which points out a toxic role of the Cu(II) – amyloid- β interaction might well be shifted towards a possible protective role when the peptides considered are the N-terminally truncated ones.

1 Introduction

1.1 Alzheimer's disease (AD)

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive cognitive and memory impairments.[1, 2] AD is the most common type of dementia in the elderly population representing 60-80% of all cases. There are two neurohistological hallmarks of AD: the amyloid (or senile) plaques, which are extracellular deposits of insoluble amyloid- β (A β) peptides under aggregated forms and the intracellular tau tangles. [3–5] The mechanisms underlying the triggering and progression of the disease are still unclear. Nevertheless, according to the amyloid cascade hypothesis first proposed in the 90's,[6] the imbalance between production and clearance of the A β peptides is at the origin of the accumulation of peptides that further leads to the aggregation of the soluble monomeric peptide into fibrils and amorphous aggregates detected in the senile plaque.[3–9] The amyloid cascade is an early event and plays a causal role in AD (Scheme 1). The

christelle.hureau@cc-toulouse.fr, <https://www.lcc-toulouse.fr/auteur59.html>.

^cCurrent address: Université de Bordeaux, ChemBioPharm INSERM U1212 CNRS UMR 5320, Bordeaux, France

complete aggregation pathway from the monomeric peptide to the fibrils contains several steps including oligomers, protofibrils and fibrils. Oligomeric species have been proposed to be the most toxic species, instigating further pathological events, including the formation of intracellular neurofibrillary tangles, destruction of synaptic connections, which would lead ultimately to neuronal cell death and dementia.[10–13] Metal ions have been involved in the amyloid cascade process based on the detection of high levels of copper and zinc in the senile plaques and on *in vitro* studies probing their abilities to modify the aggregation process.[14–18] In addition, the redox activity of copper is responsible for the production of Reactive Oxygen Species (ROS) that contribute to the oxidative stress observed in AD.[16, 19–23]

1.2 The amyloid- β peptides

Several A β peptides of various lengths are found *in vivo* and while the A $\beta_{1-40/42}$ ⁱ have been the focus of most of the reported studies, N-terminally truncated forms are also of interest since they represent a significant amount of the A β content in the brain (> 60 %). In addition, the N-terminal modifications do alter dramatically the Cu(II) binding abilities of the peptides. This will be the focus of the next paragraphs.

a APP cleavage—The A β peptides originate from the cleavage of the transmembrane Amyloid Precursor Protein (APP) by the β and γ -secretases, acting at the N- and C-terminal sites, respectively (Scheme 1). Because the C-terminal part of the A β sequence is buried in the membrane, proteolysis of the APP by the γ -secretase occurs at several sites and A β_{1-38} to A β_{1-43} peptides can be processed.[2]

b The full-length peptides—Among the “full-length” peptides (corresponding in the present review to A β_{1-38} - A β_{1-43}) the 40 and 42 amino-acid residues forms are the most abundant in the Cerebro-Spinal Fluid (CSF), with the A β_{1-42} representing 5-10% of the A β_{1-40} amount.[2] The longer form is the most toxic in line with a higher propensity to aggregate. The A β peptides encompasses a N-terminal binding site (spanning from residues 1 to 16) and a C-terminal hydrophobic sequence involved in the aggregation process. Hence, it is considered that the A β_{1-16} peptide is an appropriate model with regard to metal ion binding. This sequence is classically used in spectroscopic studies due to its higher solubility that eases its handling. It has also been extensively used to study the coordination of Cu(II), Cu(I), Zn(II) and Fe(II) to A β . [16]

c N-terminally truncated peptides—As for the C-terminal site, the N-terminal site undergoes some cleavage heterogeneity with peptides starting at positions between 1 and 5. [9, 24–26] The reason for such heterogeneity is unclear. In seminal reports by Masters and coworkers,[27, 28] the quantity of A β_{4-n} was found to be predominant in the amyloid deposits of AD patients. This was further confirmed by mass-spectrometry analyses revealing that the dominating A β species in AD brains are A β_{4-42} , A β_{1-40} and A β_{1-42} , [25] and suggesting that N-terminally truncated peptides are abundant in aged human brains.[24]

ⁱThe peptides are noted A $\beta_{n-m/p/q}$. This corresponds to a peptide starting at position n and ending at position m, or p or q and so on.

A β_{11-n} peptides are also detected in plaques from sporadic AD brains representing up to 20% of the total content of A β peptides.[29]

When the N-terminal deletion occur at position 3 or 11 corresponding to Glu residues, the formation of pyroglutamate groups can occur, leading to A β_{p3-n} and A β_{p11-n} , respectively. The pyroglutamate is generated by the action of the enzyme glutaminyl cyclase[30] and/or spontaneously but slowly over time.[29]

The various forms of the A β peptides discussed in the text are reminded in Scheme 2.

d Cu(II) binding to the A β peptides—In the present micro-review, we focus on Cu(II) binding to the various A β peptides. It is indeed anticipated that the N-terminal modifications impact significantly the Cu(II) site and affinity that will further induce changes in ROS production and aggregation of the Cu-peptide complexes, two key events linked to the amyloid cascade.

2 Techniques to study Cu(II) coordination, affinity, ROS production and peptide aggregation

2.1 Coordination sites

There are several techniques to probe the Cu(II) site in a peptide, Electron Paramagnetic Resonance (EPR) being the most appropriate due to its easy access and the large quantity of information that can be extracted from a spectrum. Indeed the values of $g_{\parallel}$, $g_{\perp}$, and of the hyperfine and super-hyperfine couplings give access to the geometry and the nature of the binding atoms.[31–34] Other techniques include UV-Vis and CD, X-ray absorption spectroscopy (both EXAFS and XANES),[35] and NMR.[32] The redox properties of the Cu-peptide complexes can be evaluated by cyclic or square-wave voltammetries.[32, 36, 37]

2.2 Affinity

There are mainly two ways of evaluating the affinity of Cu(II) for a peptide: direct titration or indirect competition experiments. In general, for direct titration experiment, quenching of the fluorescence of Tyr10 (in case of A β , but could also be Trp residues) or calorimetric (ITC) measurements are used.[38, 39] For competition experiments, any competitor having an affinity close to the one of the peptide and leading to a Cu(II) complex with a spectroscopic signature (in EPR, UV-Vis or CD) different than that the Cu(II) peptidic species can be used (see for instance, ref. [40]). Potentiometry is another accurate and direct method of establishing affinity constants. Protonation and stability constants for the Cu(II) complexes of short A β peptides, such A β_{x-16} , can be calculated from pH-metric acid-base titrations.[39]

2.3 ROS production

ROS production that corresponds to the incomplete (Cu-catalyzed) reduction of O₂ can be monitored by several indirect methods and as a function of time (Scheme 3). Consumption of ascorbate, the most classically used reductant, can be followed by UV-Vis spectroscopy at 265 nm.[22] It is almost impossible to probe the formation of superoxide due to its high rate

of reaction with ascorbate (and reduced ascorbate). Superoxide was detected via the reduction of CytC only when the Cu(A β) was reduced by electrolysis.[41] There are several tools to detect the formation of hydrogen peroxide,[22] such as the amplex red assay (formation of the resorufin luminophore) and H₂DCF assay (formation of 2,7-dichlorofluorescein) and the formation of the hydroxyl radical, such as the CCA assay (formation of the fluorescent 7-OH-CCA adduct) and TBARS assay.[22]

2.4 Aggregation

The aggregation of amyloid peptides is driven by the auto-catalytic self-assembly of monomeric peptides leading to the formation of β -sheet rich fibrils. While the kinetic of fibrils formation is mathematically described[42] by a sigmoid-like curve (see equation 1 and Scheme 4), the mechanism of amorphous aggregates formation is not well-understood.

The fibril formation displays three distinct phases. The initial phase is the lag phase, as related to the nucleation process, followed by a steep growing phase corresponding to the elongation process up to a stationary phase when the system have reached the thermodynamic equilibrium (Scheme 4). The first stage (lag phase linked to the nucleation process) is the kinetically limiting step where monomeric peptides dimerize and/or oligomerize. When a critical amount of β -sheets is reached, fast auto-assembly occurs (elongation step) finally leading to fibrils. As the system is now at its equilibrium, no more change is observed, this is the stationary phase. In order to describe the fibrils formation, two parameters are generally considered: the quantity of fibrils formed for a given starting concentration of monomeric peptides and the half-time ($t_{1/2}$), which is the time needed to reach half of the maximum of fibrils content.[43–46]

Equation 1:

$$F(t) = F_0 + \frac{A}{1 + e^{\left[-k \left(t - t_{1/2} \right) \right]}}$$

Where k is the elongation rate, A the amplitude, $t_{1/2}$ the time point when half of the maximal intensity is reached, and F_0 the baseline before aggregation.

In vitro, the A β aggregation process can monitored as a function of time by several spectroscopic techniques:[47] (i) CD by probing β -sheets content,[48] (ii) raman and infra-red spectroscopy, which provide information on secondary and tertiary structures changes at all stages of fibrillation,[49] (iii) nuclear magnetic resonance (NMR); liquid and solid state,[50–52] (iv) turbidity and light scattering,[53, 54] (v) native gel electrophoresis[55] and (vi) by addition of chromophores either changing their UV-visible absorption upon interactions with β -sheets (like Congo Red for instance)[56] or their fluorescent properties.[57, 58] A very classical assay relies on the use of Thioflavin-T (ThT), a dye that shows a characteristic red shift in the excitation spectrum and strong enhancement of fluorescence quantum yield upon binding to fibrillary structures.[59–62]

Amyloid fibrils are characterized by laminated β -sheets whose strands run perpendicular to the long-axis of the fibril.[59, 62, 63] This amyloid composition produces the characteristic ~ 5 Å and ~ 10 Å reflections observed in X-ray diffraction experiments, which are attributed to the strand spacing within and between β -sheet layers, respectively.[64]

The detection of intermediates species, especially oligomers, is more challenging. Nevertheless, various techniques can be used.[65] These methods include recognition by specific antibodies,[66] mass spectrometry,[45] FRET,[58] and electrophoresis on native gel.[67]

Furthermore, morphology of the aggregates formed can be evaluated by microscopy (Transmission Electron or Atomic Force Microscopy).[49, 68]

Each of these techniques offers advantages but also drawbacks in terms of technique-related artifacts,[45] which can anyway be overcome by using multiple independent analytical techniques in parallel.

3 Cu(II) and “full-length” A β peptides

The human A β binds preferentially one Cu(II) ion in the N-terminal domain. The rest of the sequence can modify the affinity maybe via second sphere interactions. The A β_{1-16} has been recognized as a trustworthy model for the study of Cu(II) binding to the full-length peptide. Binding of additional equivalents of Cu(II) ion has been reported[69] but is likely not biologically relevant and thus will not be commented on in the present micro-review.

Coordination site

The Cu(II) binding sites to human A β peptides have been extensively studied with various complementary techniques (e.g. EPR and advanced EPR, NMR, UV-Vis and CD, Raman and potentiometry) and has been recently reviewed.[16, 33, 34] Briefly, around neutral pH, the Cu(II)-(A β) complex exists in two main forms, noted component I (predominant at lower pH) and II (predominant at higher pH) (Scheme 5.A). Component II is obtained from component I by the deprotonation of an amide bond of the peptide backbone and subsequent binding to the Cu(II). The pK_a corresponding to the transition between I and II is near pH 7.8. Both forms bind the Cu(II) in a distorted square planar geometry. In component I, Cu(II) is equatorially bound to Asp1 via the terminal amine, the adjacent CO from the Asp1-Ala2 peptide bond, a N atom from imidazole ring of His6 and another one from His13 (component Ia) or from His14 (component Ib) or two N atoms from the His13 and 14 (component Ic). The apical position may be occupied by an oxygen atom, coming either from a water molecule,[70] or from carboxylate groups from side chains of Asp or Glu.[71] In component II, the main equatorial Cu(II) ligands are the N-terminal amine, the amidyl function from the Asp1-Ala2 peptide bond, the adjacent CO from the Ala2-Glu3 peptide bond, and one N atom from the imidazole ring of one of the three His. The carboxylate group from Asp1 has been proposed as apical ligand,[70] likely via a water molecule as bridge.

Affinity

As stated above, the high affinity Cu(II) binding site is located in the first 16 N-terminal residues. There are many reports on the evaluation of the Cu(II) affinity for the A β peptide. The divergence in the affinity value between studies originated from the use of different evaluation methods.[39] This has recently been sorted out,[38, 40] and a conditional value of $1.6 \cdot 10^9 \text{ M}^{-1}$ at pH 7.1 and of $1.1 \cdot 10^{10} \text{ M}^{-1}$ at pH 7.4 for the A β_{1-16} make consensus (the conditional value is the value at a given pH with no competing buffer).[72] The Cu(II) affinity seems to weakly increase with the length of peptide.[38, 40, 72, 73]

ROS production

The ability of Cu(A β) complexes to generate ROS is in line with the hypothesis that they participate in the oxidative stress observed in AD brains post mortem.[74] Such an ability relies on the possibility to have a reaction between the reductant (the physiological one is ascorbate) and the Cu^{II}(A β) and between the Cu^I(A β) and dioxygen, superoxide and/or hydrogen peroxide. Those reactions were recently probed by several methods (see § 2.3) and it was shown that (i) the Cu(A β) do produce ROS, (ii) the rate of ROS production is weaker than for “loosely bound” Cu, corresponding to Cu in buffer and (iii) the rate is significant if compared to other biologically relevant peptides, such as GHK and DAHK.[74–79] A direct comparison between ROS production by “loosely bound” Cu and Cu(A β) species is difficult since it will depend on the experimental conditions (concentrations in Cu, ascorbate, dioxygen and peptides). Hence, the ascorbate consumption rate of Cu(A β) is about half that of “loosely bound” Cu. The length of the peptide has almost no impact on the ROS production rate, but because the peptide can itself be oxidized by the ROS produced, the quantity of ROS escaping the system is weaker when the peptide is longer. [74]

Aggregation

The effect of the Cu(II) on A $\beta_{1-40/42}$ aggregation has been discussed widely,[17, 43, 80] and consensus takes long time to be reached. Indeed, a major controversial point is due to the intrinsic complex nature of A β aggregates. Amorphous or/and fibrillar aggregates could be formed from monomeric A β . Depending of analytical techniques used, researchers were able (or not) to discriminate the nature of the aggregates. Also, experimental parameters such Cu(II) / A β stoichiometry or pH seem to have a dramatic impact on the outcome of aggregation assays. Nowadays, studies seem to converge on different aspects. On one hand, the presence of sub-stoichiometric Cu(II) seems to accelerate the formation of fibrillar aggregates[81] likely due to a metal-mediated dimerization,[82, 83] and a stabilization of oligomers.[84, 85] On the other hand, in excess, Cu(II) generates more amorphous and less fibrillar aggregates.[86–88] It has also been shown that removing Cu(II) from A β amorphous aggregates using an external chelator restore fibrillary-type aggregates.[89] Another key parameter in the A β aggregation is the pH. It has been shown that A β aggregation occurs faster at acidic pH,[90, 91] and Cu(II) is able to interact with A β aggregation even at mildly acid pH,[92] in a rapid time frame.[93] Nevertheless, below pH=5, Cu(II) do not impact A β aggregation,[82] likely due to its inability to strongly interact with A β .[73]

4 N-truncated peptides

4.1 ATCUN type motifs

For a long time the “full-length” $A\beta_{1-40/42}$ peptides (or the corresponding C-terminally truncated forms $A\beta_{1-16/28}$) have been the primary focus of Cu(II) binding studies.[16] However, it has been reported that the N-truncated $A\beta_{4-42}$ peptide is one of the major form of $A\beta$ peptides detected in healthy and diseased brains,[24–28] representing more than 60% of the total brain amyloid pool. N-truncation also lead to the formation of the $A\beta_{11-40/42}$. [94–96] The $A\beta_{4-40/42}$ and $A\beta_{11-40/42}$ peptide share a common feature with respect to Cu(II) binding site, since they present a N-terminal ATCUN (amino-terminal copper and nickel) motif characterized by the sequence H2N-Xxx-Yyy-His.[97, 98] It is worth noting that a main difference between the $A\beta_{4-x}$ and $A\beta_{11-x}$ is the possibility for the latter to form pyroglutamate counterparts. Hence, while the $A\beta_{11-40/42}$ have been detected in large quantity in the CSF and amyloid plaques,[29, 94, 99–101] they can degrade rapidly into pyroglutamate forms.[25, 94]

Such N-terminal truncations, which can also happen at other sites between Asp1 and Arg5, are linked to the enzymatic cleavage activity of secretases that depends on many factors as reviewed in ref. [9]. The formation of the $A\beta_{11-40/42}$ peptide is due to the activity of a secondary β -secretase (β').[95, 96, 102]

Coordination site—ATCUN containing peptides can bind Cu(II) avidly because the binding site is made of three adjacent metallacycles of 5, 5 and 6 membered rings, the Cu(II) being bound by the N-terminal amine, the imidazole ring from the His and the two deprotonated peptidic functions in between. [77, 97, 98] The ATCUN coordination mode of Cu(II) to $A\beta_{4-n}$ and to $A\beta_{11-n}$ is predominant from pH 5, while deprotonation of outer-sphere and non-binding side chains occurs when the pH is increased.[103–105] A weak fifth ligand, a water molecule, can be present as apical ligand. This coordination is analogous to the one proposed for the DAHK tetrapeptide, the N-terminal sequence of human serum albumin, the structure of which was resolved by X-ray diffraction.[77] The spectroscopic signatures of Cu($A\beta_{4-16}$) and Cu($A\beta_{11-15}$) used as models of the $A\beta_{4-42}$ and $A\beta_{11-42}$ peptide, are fully reminiscent of those of the Cu(II) parent complexes, such as Cu(DAHK) and Cu(AAH) (See Table 1). The formation of such ATCUN motif would preclude the formation of ternary species between Cu($A\beta_{4/11-x}$) and a chelating drug candidate,[106] in contrast to what has been reported in case of the $A\beta_{1-x}$ peptide.[106–108]

Affinity—While Cu(II) binds to $A\beta_{1-16}$ with a relatively high affinity ($K_a \sim 10^{10} \text{ M}^{-1}$ at pH 7.4, see table 1), $A\beta_{4-16}$ and $A\beta_{11-15}$, bind Cu(II) with a very high affinity ($K_a \sim 10^{13.5} \text{ M}^{-1}$ at pH 7.4) through their ATCUN motif (Scheme 5D).[103, 104] Such affinity is perfectly in line with those of other ATCUN peptides.[109, 110] Note that a secondary Cu(II) site is present in $A\beta_{4-16}$ and is relatively weak ($K_a = 10^{6.7} \text{ M}^{-1}$ at pH=7.4) and separated from the N-terminal site.[103] The more than three orders of magnitude higher affinity for Cu(II) compared to the full-length peptides make these peptides key biological partners in the trafficking of Cu(II) within the synaptic cleft.

ROS production—Up to now, the ROS production has only been studied with the A β ₄₋₁₆. It has been shown that Cu(A β _{4-x}) can only be oxidized and at relatively high cathodic potential (0.8 V *vs.* SCE) and that, in line with this redox properties, it doesn't yield ROS under biologically relevant conditions.[111] The other truncated ATCUN-type A β peptides A β _{11-x} might have similar properties to those of A β ₄₋₄₂. However it remains to be determined if the ATCUN site of A β _{11-x} peptides can undergo redox cycling and generate ROS.

Aggregation—As non-truncated A β , A β _{4-40/42} is also able to aggregate and cause cell toxicity and memory impairment in mice. *In vitro* experiments have also shown that in ThT fluorescence assay, the maximal ThT intensities reached by A β _{4-38/40/42} were similar to the one of A β ₁₋₄₂, but decreased faster. This could be explained by a burial of ThT-binding site as aggregates evolve. TEM images showed an important difference in the morphology at the aggregation end-point: the N-truncated peptide showed clumps of fibrillar aggregates, while A β ₁₋₄₂ show longer individual fibrils.[112] A β ₁₁₋₄₀ forms fibrils faster than A β ₁₋₄₀ and A β ₁₋₄₂ and it does co-assemble with A β ₁₋₄₀ but not A β ₁₋₄₂. [104, 113] Cu(II) addition to A β _{11-28/40/42} seems to preclude fibrillary aggregation,[104, 114, 115] likely due to the strong 1:1 Cu(II) - ATCUN coordination that destabilize peptide-peptide interactions required for the nucleation of the aggregation process.[44]

4.2 Other motifs

N-terminal truncated peptides in position 3 and their pyroglutamate counterparts have been found in high amount in the brain of Alzheimer's patients (up to 25% of the plaques content).[116, 117] These peptides are considered to be more toxic than the full-length ones, [118–131] in link with modified plaque morphology, hampered degradation of the pyroglutamate forms, higher propensity to form β -sheets and impact on full-length peptides aggregation process. Formation of pyroglutamate at position 11 (see previous paragraph) is also possible but its effect has been less studied.[124, 132, 133]

Coordination site—Despite the similarity between the sequences of A β ₁₋₁₆ and A β ₃₋₁₆, the Cu(II) binding sites to the A β ₃₋₁₆ peptide are significantly different to those of A β ₁₋₁₆. The main form of Cu(A β ₃₋₁₆) at pH 7.4 is a component II-like and is shown in Scheme 5C. The equatorial Cu(II) coordination is made of the N-terminal amine, an amidyl function from the Glu3-Phe4 peptide bond, the imidazole ring of His6 and the carbonyl function from the His6-Asp7 bond.[134] Such differences has been explained by second sphere interactions, such as the size of cycle due to the H-bond between the side chain of Asp1 or Glu3 and the adjacent amide function.

The formation of the pyroglutamate in A β _{p3-16} precludes the binding of the N-terminal amine (Scheme 5D) and induces subsequent changes. In the main form present at neutral pH, the Cu(II) is thus bound by two imidazole rings from His 13 and 14, the amidyl function of His13-His14 bond and either carboxylate function or a N atom from the imidazole ring of His6.[134]

Affinity—The affinity values of Cu(II) for the A β ₃₋₁₆ and the A β _{p3-16} are three and hundred times weaker than the one of A β ₁₋₁₆, respectively. The strong decrease in the affinity of the A β _{p3-16} is due to the preclusion of the N-terminal binding and has also been reported for the N-terminally acetylated Ac-A β peptide.[134, 135]

ROS—It has been shown recently that N-terminal modification at the third position significantly slow down the ROS production rate while keeping the amount of ROS escaping the Cu(A β ₃₋₁₆) or Cu(A β _{p3-16}) complex unchanged. This was attributed to the importance of the N-terminal Asp1 residues in the catalytically active Cu(A β ₁₋₁₆) species.[74]

Aggregation—To the best of our knowledge, there is no study on the impact of Cu(II) on the aggregation of A β _{3-40/42}, A β _{p3-40/42} and A β _{p11-40/42}.

5 Concluding remarks

As reminded in Table 1, N-terminal modifications strongly impact the Cu(II) binding site, both from a structural view or a thermodynamic one. The most striking difference might well be the Cu(II) affinity of the A β _{4/11-16} peptides compared to the one of A β ₁₋₁₆. Such more than three orders of magnitude higher affinity will thus impact Cu(II) trafficking within the synaptic cleft and between peptides. Another key point is that all N-terminally truncated peptides has a weaker (up to a negligible) ability to produce ROS compared to the full-length peptide.

However, from the results and data described above, it appears that some studies are still missing to better decipher the importance of N-terminally truncated A β peptides in AD. In particular and as recently studied for A β ₁₋₁₆, [137] the interference of Zn in Cu(II) binding should be addressed. Aggregation studies of N-terminally truncated A β peptides in presence of Cu(II) are also too scarce. It would also be very interesting to study the co-aggregation of several forms of A β peptides as recently done for A β ₁₁₋₄₀, A β ₁₋₄₀ and A β ₁₋₄₂ [113] but in presence of Cu(II).

As stated above, the difference in affinity and ROS production ability between the full-length and N-terminally truncated peptides is of importance. Indeed, because A β _{4/11-16/40} can (i) remove Cu(II) from A β and (ii) redox silence it, those peptides appear as extremely beneficial in the context of AD in link with oxidative stress, to which the ROS produced by the Cu(II)-A β system may contribute.

As a direct consequence, modifying the production of the A β peptide to favor cleavage at position 4 or 11 appears as a new therapeutic approach, at least with regards to the interaction with Cu(II). More generally, N-terminally peptides might also be considered as new therapeutic targets.[9]

To briefly conclude and as previously pointed out in seminal works,[103, 104, 111, 134, 136] the interaction of Cu(II) with N-terminally truncated peptides might reshape the current vision of a deleterious impact of Cu(II) binding to amyloid- β peptides.

Acknowledgments

The ERC aLzINK grant (ERC-StG-638712) is acknowledged for financial support. We thank Prof. Peter Faller, students and associated researchers of the “Alzheimer and amyloids” team for their contributions in several of the results described in the present review.

Abbreviations

Aβ	Amyloid- β Peptides
AD	Alzheimer Disease
AFM	Atomic Force Microscopy
APP	Amyloid Precursor Protein
ATCUN	Amino Terminal Cu(II) and Ni(II) binding motif (H ₂ N-Xxx-Yyy-His)
CCA	Coumarin Carboxylic Acid
CD	Circular Dichroism
CSF	Cerebro-Spinal Fluid
EPR	Electron Paramagnetic Resonance
EXAFS	Extended X-Ray Absorption Fine Structure
FRET	Fluorescence Resonance Energy Transfer
ITC	Isothermal Titration Calorimetry
H₂-DCF	dichlorodihydrofluorescein diacetate
ROS	Reactive Oxygen Species
SCE	Saturated Calomel Electrode
TBARS	2-Thiobarbituric Acid Reactive Substances
TEM	Transmission Electron Microscopy
ThT	Thioflavine T
XANES	X-Ray Absorption Near Edge Structure

References

- [1]. Selkoe DJ. *Physiol Rev.* 2001; 81:741–766. [PubMed: 11274343]
- [2]. Holtzman DM, Morris JC, Goate AM. *Sci Transl Med.* 2011; 3:77sr71.
- [3]. Goedert M, Spillantini MG. *Science.* 2006; 314:777–781. [PubMed: 17082447]
- [4]. Hardy J, Selkoe DJ. *Science.* 2002; 297:353–356. [PubMed: 12130773]
- [5]. Maccioni RB, Muñoz JP, Barbeito L. *Arch Med Res.* 2001; 32:367–381. [PubMed: 11578751]
- [6]. Hardy JA, Higgins GA. *Science.* 1992; 256:184–185. [PubMed: 1566067]
- [7]. Reitz C. *J Alzheimers Dis.* 2012; 2012:11.

- [8]. Karran E, Mercken M, De Strooper B. *Nature Reviews*. 2011; 10:698–712.
- [9]. Bayer TA, Wirths O. *Acta Neuropathol (Berl)*. 2014; 128:787–801.
- [10]. Kaye R, Lasagna-Reeves CA. *J Alzheimers Dis*. 2013; (Suppl1):S67–78. [PubMed: 22531422]
- [11]. Meenakshi V, Abhishek V, Vibha T. *Ann Indian Acad Neurol*. 2015; 18:138–145. [PubMed: 26019408]
- [12]. Sengupta U, Nilson AN, Kaye R. *EBioMedicine*. 2016; 6:42–49. [PubMed: 27211547]
- [13]. Benilova I, Karran E, De Strooper B. *Nat Neurosci*. 2012; 15:349–357. [PubMed: 22286176]
- [14]. Gaggelli E, Kozlowski H, Valensin D, Valensin G. *Chem Rev*. 2006; 106:1995–2044. [PubMed: 16771441]
- [15]. Barnham KJ, Bush AI. *Chem Soc Rev*. 2014; 43:6727–6749. [PubMed: 25099276]
- [16]. Hureau C. *Coord Chem Rev*. 2012; 256:2164–2174.
- [17]. Viles JH. *Coord Chem Rev*. 2012; 256:2271–2284.
- [18]. Roychaudhuri R, Yang M, Hoshi MM, Teplow DB. *J Biol Chem*. 2009; 284:4749–4753. [PubMed: 18845536]
- [19]. Smith DG, Cappai R, Barnham KJ. *Biochim Biophys Acta*. 2007; 1768:1976–1990. [PubMed: 17433250]
- [20]. Smith MA, Rottkamp CA, Nunomura A, Raina AK, Perry G. *Biochimica et Biophysica Acta - Molecular Basis of Disease*. 2000; 1502:139–144.
- [21]. Hureau C, Faller P. *Biochimie*. 2009; 91:1212–1217. [PubMed: 19332103]
- [22]. Chassaing S, Collin F, Dorlet P, Gout J, Hureau C, Faller P. *Curr Top Med Chem*. 2012; 12:2573–2595. [PubMed: 23339309]
- [23]. Perry G, Cash AD, Smith MA. *J Biomed Biotechnol*. 2002; 2:120–123. [PubMed: 12488575]
- [24]. Lewis H, Behr D, Cookson N, Oakley N, Piggott M, Morris CM, Jaros E, Perry R, Ince P, Kenny RA, Ballard CG, et al. *Neuropathol Appl Neurobiol*. 2006; 32:103–118. [PubMed: 16599940]
- [25]. Portelius EB, Gustavsson NMK, Volkman I, Brinkmalm G, Zetterberg H, Winblad B, Blennow K. *Acta Neuropathol*. 2010; 120:185–193. [PubMed: 20419305]
- [26]. Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K, Westman-Brinkmalm A. *J Proteome Res*. 2007; 6:4433–4439. [PubMed: 17927230]
- [27]. Masters CL, Multhaup G, Simms G, Pottgiesser J, Martins RN, Beyreuther K. *EMBO J*. 1985; 4:2757–2763. [PubMed: 4065091]
- [28]. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. *Proc Natl Acad Sci U S A*. 1985; 82:4245–4249. [PubMed: 3159021]
- [29]. Liu K, Solano I, Mann D, Lemere C, Mercken M, Trojanowski JQ, Lee VM. *Acta Neuropathol*. 2006; 112:163–174. [PubMed: 16865398]
- [30]. Seifert F, Demuth HU, Weichler T, Ludwig HH, Tittmann K, Schilling S. *Bioorg Chem*. 2015; 60
- [31]. Dorlet P, Hureau C. *Étude de complexes de cuivre associés aux maladies neurodégénératives*. Bertrand P, editor Vol. 7. EDP Grenoble Sciences; 2014. 263–290.
- [32]. Faller P, Hureau C, Dorlet P, Hellwig P, Coppel Y, Collin F, Alies B. *Coord Chem Rev*. 2012; 256:2381–2396.
- [33]. Drew SC, Barnham KJ. *Acc Chem Res*. 2011; 44:1146–1155. [PubMed: 21714485]
- [34]. Hureau C, Dorlet P. *Coord Chem Rev*. 2012; 256:2175–2187.
- [35]. Faller P, Hureau C. *Actualité Chimique*. 2011; 356–357:88–90.
- [36]. Hureau C, Balland V, Coppel Y, Solari PL, Fonda E, Faller P. *J Biol Inorg Chem*. 2009:995–1000. [PubMed: 19618220]
- [37]. Balland V, Hureau C, Savéant J-M. *Proc Natl Acad Sci U S A*. 2010; 107:17113–17118. [PubMed: 20858730]
- [38]. Alies B, Renaglia E, Rozga M, Bal W, Faller P, Hureau C. *Anal Chem*. 2013; 85:1501–1508. [PubMed: 23249207]
- [39]. Zawisza I, Rozga M, Bal W. *Coord Chem Rev*. 2012; 256:2297–2307.
- [40]. Conte-Daban A, Borghesani V, Sayen S, Guillon E, Journaux Y, Gontard G, Lisnard L, Hureau C. *Anal Chem*. 2017; 89:2155–2162. [PubMed: 28208266]

- [41]. Reybier K, Ayala S, Alies B, Bustos Rodriguez S, Rodrigues J, Gomes C, La Penna G, Collin F, Hureau C, Faller P. *Angewandte Chemie international Edition*. 2016; 55:1085–1089. [PubMed: 26629876]
- [42]. Hellstrand E, Boland B, Walsh DM, Linse S. *ACS Chem Neurosci*. 2010; 1:13–18. [PubMed: 22778803]
- [43]. Faller P, Hureau C, Berthoumieu O. *Inorg Chem*. 2013; 52:12193–12206. [PubMed: 23607830]
- [44]. Alies B, Hureau C, Faller P. *Metallomics*. 2013; 5:183–192. [PubMed: 23416948]
- [45]. Bartolini M, Naldi M, Fiori J, Valle F, Biscarini F, Nicolau DV, Andrisano V. *Anal Biochem*. 2011; 414:215–225. [PubMed: 21435333]
- [46]. del Barrio M, Borghesani V, Hureau C, Faller P. *Biometals in Neurodegenerative Diseases: Mechanisms and Therapeutics*. 2017:1–30.
- [47]. Tiwari V, Solanki V, Tiwari M. *Frontiers in Life Science*. 2015; 8:332–347.
- [48]. Bartolini M, Bertucci C, Bolognesi ML, Cavalli A, Melchiorre C, Andrisano V. *ChemBioChem*. 2007; 8:2152–2161. [PubMed: 17939148]
- [49]. Kurouski D, Van Duyne RP, Lednev IK. *Analyst*. 2015; 140:4967–4680. [PubMed: 26042229]
- [50]. Hou L, Shao H, Zhang Y, Li H, Menon NK, Neuhaus EB, Brewer JM, Byeon IJ, Ray DG, Vitek MP, Iwashita T, et al. *J Am Chem Soc*. 2004; 126:1992–2005. [PubMed: 14971932]
- [51]. Karamanos TK, Kalverda AP, Thompson GS, Radford SE. *Prog Nucl Magn Reson Spectrosc*. 2015; 88–89:86–104.
- [52]. Baldus M. *Eur Biophys J*. 2007; 36:37–48.
- [53]. Alies B, Solari PL, Hureau C, Faller P. *Inorg Chem*. 2012; 51:701–708. [PubMed: 22148916]
- [54]. Shen CL, Scott GL, Merchant F, Murphy RM. *Biophys J*. 1993; 65:2383–2395. [PubMed: 8312477]
- [55]. Klug GMJA, Losic D, Subasinghe Supundi S, Aguilar M-I, Martin LL, Small DH. *Eur J Biochem*. 2003; 270:4282–4293. [PubMed: 14622293]
- [56]. Klunk WE, Jacob RF, Mason RP. *Anal Biochem*. 1999; 266:66–76. [PubMed: 9887214]
- [57]. Jameson LP, Smith NW, Dzyuba SV. *ACS Chem Neurosci*. 2012; 3:807–819. [PubMed: 23173064]
- [58]. Aliès B, Eury H, Essassi EM, Pratviel G, Hureau C, Faller P. *Anal Chem*. 2014; 86:11877–11882. [PubMed: 25380342]
- [59]. Biancalana M, Koide S. *Biochim Biophys Acta*. 2010; 1804:1405–1412. [PubMed: 20399286]
- [60]. Groenning M, Olsen L, van de Weert M, Flink JM, Frokjaer S, Førgensen FS. *J Struct Biol*. 2007; 158:358–369. [PubMed: 17289401]
- [61]. Amdursky N, Erez Y, Huppert D. *Acc Chem Res*. 2012; 45:1548–1557. [PubMed: 22738376]
- [62]. Noël S, Cadet S, Gras E, Hureau C. *Chem Soc Rev*. 2013; 42:7747–7762. [PubMed: 23793644]
- [63]. Nelson R, Eisenberg D. *Curr Opin Struct Biol*. 2006; 16:260–265. [PubMed: 16563741]
- [64]. Guijarro JI, Sunde M, Jones JA, Campbell ID, Dobson CM. *Proc Natl Acad Sci U S A*. 1998; 95:4224–4228. [PubMed: 9539718]
- [65]. Pryor NE, Moss MA, Hestekin CN. *International Journal of Molecular Sciences*. 2012; 13:3038–3072. [PubMed: 22489141]
- [66]. Goure WF, Krafft GA, Jerecic J, Hefti F. *Alzheimer's Research & Therapy*. 2014; 6:42.
- [67]. Iura cu MI, Cozma C, Tomczyk N, Rontree J, Desor M, Drescher M, Przybylski M. *Anal Bioanal Chem*. 2009; 395:2509–2519. [PubMed: 19838688]
- [68]. Drolle E, Hane F, Lee B, Leonenko Z. *Drug Metab Rev*. 2014; 46:207–223. [PubMed: 24495298]
- [69]. Guilloureaux L, Damian L, Coppel Y, Mazarguil H, Winterhalter M, Faller P. *J Biol Inorg Chem*. 2006; 11:1024–1038. [PubMed: 16924555]
- [70]. Kim D, Kim NH, Kim SH. *Angew Chem, Int Ed Engl*. 2013; 52:1139–1142. [PubMed: 23208892]
- [71]. Hureau C, Coppel Y, Dorlet P, Solari PL, Sayen S, Guillon E, Sabater L, Faller P. *Angew Chem, Int Ed Engl*. 2009; 48:9522–9525. [PubMed: 19904787]
- [72]. Faller P, Hureau C. *Dalton Trans*. 2009:1080–1094. [PubMed: 19322475]

- [73]. Kowalik-Jankowska T, Ruta M, Wisniewska K, Lankiewicz L. *J Inorg Biochem.* 2003; 95:270–282. [PubMed: 12818797]
- [74]. Cheignon C, Jones M, Atrian-Blasco E, Kieffer I, Faller P, Collin F, Hureau C. *Chem Sci.* 2017
- [75]. Cheignon C, Faller P, Testemale D, Hureau C, Collin F. *Metallomics.* 2016; 8:1081–1089. [PubMed: 27730227]
- [76]. Cheignon C, Collin F, Faller P, Hureau C. *Dalton Trans.* 2016; 45:12627–12631. [PubMed: 27264439]
- [77]. Hureau C, Eury H, Guillot R, Bijani C, Sayen S, Solari PL, Guillon E, Faller P, Dorlet P. *Chem Eur J.* 2011; 17:10151–10160. [PubMed: 21780203]
- [78]. Yako N, Young TR, Cottam Jones JM, Hutton CA, Wedd AG, Xiao Z. *Metallomics.* 2017
- [79]. Pedersen JT, Chen SW, Borg CB, Ness S, Bahl JM, Heegaard NH, Dobson CM, Hemmingsen L, Cremades N, Teilum K. *J Am Chem Soc.* 2016; 138:3966–3969. [PubMed: 26967463]
- [80]. Faller P. *ChemBioChem.* 2009; 10:2837–2845. [PubMed: 19877000]
- [81]. Sarell CJ, Wilkinson SR, Viles JH. *J Biol Chem.* 2010; 285:41533–41540. [PubMed: 20974842]
- [82]. Lv Z, Condrón MM, Teplow DB, Lyubchenko YL. *Journal of Neuroimmune Pharmacology.* 2013; 8:262–273. [PubMed: 23143330]
- [83]. Hane F, Tran G, Attwood SJ, Leonenko Z. *PLOS ONE.* 2013; 8:e59005. [PubMed: 23536847]
- [84]. Chen W-T, Liao Y-H, Yu H-M, Cheng IH, Chen Y-R. *J Biol Chem.* 2011; 286:9646–9656. [PubMed: 21216965]
- [85]. Matheou CJ, Younan ND, Viles JH. *Biochem J.* 2015; 466:233–242. [PubMed: 25471541]
- [86]. Pedersen JT, Østergaard J, Rozlosnik N, Gammelgaard B, Heegaard NH. *J Biol Chem.* 2011; 286:26952–26963. [PubMed: 21642429]
- [87]. Mold M, Ouro-Gnao L, Wieckowski BM, Exley C. *Scientific Reports.* 2013; 3:1256. [PubMed: 23409247]
- [88]. Jun S, Gillespie JR, Shin B-k, Saxena S. *Biochemistry.* 2009; 48:10724–10732. [PubMed: 19824649]
- [89]. Töugu V, Karafin A, Zovo K, Chung RS, Howells C, West AK, Palumaa P. *J Neurochem.* 2009; 110:1785–1795.
- [90]. Snyder SW, Lador US, Wade WS, Wang GT, Barrett LW, Matayoshi ED, Huffaker HJ, Krafft GA, Holzman TF. *Biophys J.* 1994; 67:1216–1228. [PubMed: 7811936]
- [91]. Atwood CS, Moir RD, Huang X, Scarpa RC, Bacarra NM, Romano DM, Hartshorn MA, Tanzi RE, Bush AI. *J Biol Chem.* 1998; 273:12817–12826. [PubMed: 9582309]
- [92]. Pedersen JT, Borg CB, Michaels TCT, Knowles TPJ, Faller P, Teilum K, Hemmingsen L. *ChemBioChem.* 2015; 16:1293–1297. [PubMed: 25989377]
- [93]. Pedersen JT, Teilum K, Heegaard NHH, Østergaard J, Adolph H-W, Hemmingsen L. *Angew Chem, Int Ed Engl.* 2011; 50:2532–2535. [PubMed: 21370331]
- [94]. Näslund J, Schierhorn A, Hellman U, Lannfelt L, Roses AD, Tjernberg LO, Silberring J, Gandy SE, Winblad B, Greengard P, Nordstedt C, et al. *Proc Natl Acad Sci U S A.* 1994; 91:8378–8382. [PubMed: 8078890]
- [95]. Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, Teplow DB, Ross S, Amarante P, Loeloff R, Luo Y, et al. *Science (Washington, D. C., 1883-).* 1999; 286:735–741.
- [96]. Huse JT, Liu K, Pijak DS, Carlin D, Lee VM, Doms RW. *J Biol Chem.* 2002; 277:16278–16284. [PubMed: 11847218]
- [97]. Harford C, Sarkar B. *Acc Chem Res.* 1997; 30:123–130.
- [98]. Bal W, Sokołowska M, Kurowska E, Faller P. *Biochim Biophys Acta.* 2013; 1830:5444–5455. [PubMed: 23811338]
- [99]. Seubert P, Vigo-Pelfrey C, Esch F, Lee M, Dovey H, Davis D, Sinha S, Schlossmacher M, Whaley J, Swindlehurst C, McCormack R, et al. *Nature (London).* 1992; 359:325–327. [PubMed: 1406936]
- [100]. Miravalle L, Calero M, Takao M, Roher AE, Ghetti B, Vidal R. *Biochemistry.* 2005; 44:10810–10821. [PubMed: 16086583]

- [101]. Miller DL, Papayannopoulos IA, Styles J, Bobin SA, Lin YY, Biemann K, Iqbal K. Arch Biochem Biophys. 1993; 301:41–52. [PubMed: 8442665]
- [102]. Thinakaran G, Koo EH. J Biol Chem. 2008; 283:29615–29619. [PubMed: 18650430]
- [103]. Mital M, Wezynfeld NE, Frczyk T, Wiloch MZ, Wawrzyniak UE, Bonna A, Tumpach C, Barnham KJ, Haigh CL, Bal W, Drew SC. Angew Chem Int Ed. 2015; 54:10460–10464.
- [104]. Barritt JD, Viles JH. J Biol Chem. 2015; 290:27791–27802. [PubMed: 26408196]
- [105]. Karr JW, Akintoye H, Kaupp LJ, Szalai VA. Biochemistry. 2005; 44:5478–5487. [PubMed: 15807541]
- [106]. Mital M, Zawisza IA, Wiloch MZ, Wawrzyniak UEK, Wróblewski VW, Bal W, Drew SC. Inorg Chem. 2016; 55:7317–7319. [PubMed: 27409140]
- [107]. Kenche VB, Zawisza IA, Masters CL, Bal W, Barnham KJ, Drew SC. Inorg Chem. 2013; 52:4303–4318. [PubMed: 23537393]
- [108]. De Ricco R, Valensin D, Dell'Acqua S, Casella L, Hureau C, Faller P. ChemBioChem. 2015; 16:2319–2328. [PubMed: 26338312]
- [109]. Trapaidze A, Hureau C, Bal W, Winterhalter M, Faller P. J Biol Inorg Chem. 2012; 17:37–47. [PubMed: 21898044]
- [110]. Sokolowska M, Krezel A, Dyba M, Szewczuk Z, Bal W. Eur J Biochem. 2002; 269:1323–1331. [PubMed: 11856367]
- [111]. Wezynfeld NE, Stefaniak E, Stachucy K, Drozd A, Plonka D, Drew SC, Krel A, Bal W. Angew Chem Int Ed. 2016; 55:8235–8238.
- [112]. Bouter Y, Dietrich K, Wittnam JL, Rezaei-Ghaleh N, Pillot T, Papot-Couturier S, Lefebvre T, Sprenger F, Wirths O, Zweckstetter M, Bayer TA. Acta Neuropathol (Berl). 2013; 126:189–205. [PubMed: 23685882]
- [113]. Viles JH, Barritt JD, Younan ND. Angew Chem Int Ed. 2017; doi: 10.1002/anie.201704618
- [114]. Pradines V, Jurca Stroia A, Faller P. New J Chem. 2008; 32:1189–1194.
- [115]. Alies B, Pradines V, Alliot I, Sayen S, Guillon E, Hureau C, Faller P. J Biol Inorg Chem. 2011; 16:333–340. [PubMed: 21061029]
- [116]. Jawhar S, Wirths O, Bayer TA. J Biol Chem. 2011; 286:38825–38832. [PubMed: 21965666]
- [117]. Harigaya Y, Saido TC, Eckman CB, Prada CM, Shoji M, Younkin SG. Biochem Biophys Res Commun. 2000; 276:422–427. [PubMed: 11027491]
- [118]. Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth HU, Blennow K, Wirths O, Bayer TA. J Biol Chem. 2012; 287:8154–8162. [PubMed: 22267726]
- [119]. Wirths O, Breyhan H, Cynis H, Schilling S, Demuth HU, Bayer TA. Acta Neuropathol (Berl). 2009; 118:487–496. [PubMed: 19547991]
- [120]. Schlenzig D, Röncke R, Cynis H, Ludwig HH, Scheel E, Reymann K, Saido T, Hause G, Schilling S, Demuth HU. J Neurochem. 2012; 121:774–784. [PubMed: 22375951]
- [121]. Schilling S, Zeitschel U, Hoffmann T, Heiser U, Francke M, Kehlen A, Holzer M, Hutter-Paier B, Prokesch M, Windisch M, Jagla W, et al. Nat Med. 2008; 14:1106–1111. [PubMed: 18836460]
- [122]. Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth HU, Lemere CA. Neurodegener Dis. 2012; 10:265–270. [PubMed: 22343072]
- [123]. Wirths O, Bethge T, Marcello A, Harmeyer A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, et al. J Neural Transm. 2010; 117:85–96. [PubMed: 19823761]
- [124]. Schlenzig D, Manhart S, Cinar Y, Kleinschmidt M, Hause G, Willbold D, Funke SA, Schilling S, Demuth HU. Biochemistry. 2009; 48:7072–7078. [PubMed: 19518051]
- [125]. Schilling S, Lauber T, Schaupp M, Manhart S, Scheel E, Böhm G, Demuth HU. Biochemistry. 2006; 45:12393–12399. [PubMed: 17029395]
- [126]. Nussbaum JM, Schilling S, Cynis H, Silva A, Swanson E, Wangsanut T, Tayler K, Wiltgen B, Hatami A, Röncke R, Reymann K, et al. Nature. 2012; 485:651–655. [PubMed: 22660329]
- [127]. Güntert A, Döbeli H, Bohrmann B. Neuroscience. 2006; 143:461–475. [PubMed: 17008022]

- [128]. Dammers C, Reiss K, Gremer L, Lecher J, Ziehm T, Stoldt M, Schwarten M, Willbold D. *Biophys J*. 2017; 112:1621–1633. [PubMed: 28445753]
- [129]. Tomaselli S, Pagano K, D'Arrigo C, Molinari H, Ragona L. *ACS Chem Neurosci*. 2017; 8:759–765. [PubMed: 28135060]
- [130]. Meißner JN, Bouter Y, Bayer TA. *J Alzheimers Dis*. 2015; 45:471–482. [PubMed: 25547635]
- [131]. Wulff M, Baumann M, Thimmeler A, Yadav JK, Heinrich L, Knîpfer U, Schlenzig D, Schierhorn A, Rahfeld J-U, Horn U, Balbach J, et al. *Angew Chem Int Ed*. 2016; 55
- [132]. Sohma Y, Yamasaki M, Kawashima H, Taniguchi A, Yamashita M, Akaji K, Mukai H, Kiso Y. *Bioorg Med Chem Lett*. 2013; 23:1326–1329. [PubMed: 23352512]
- [133]. Sullivan CP, Berg EA, Elliott-Bryant R, Fishman JB, McKee AC, Morin PJ, Shia MA, Fine RE. *Neurosci Lett*. 2011; 505:109–112. [PubMed: 22001577]
- [134]. Alies B, Bijani C, Sayen S, Guillon E, Faller P, Hureau C. *Inorg Chem*. 2012; 51:12988–13000. [PubMed: 23150940]
- [135]. Young TR, Kirchner A, Wedd AG, Xiao Z. *Metallomics*. 2014; 6:505–517. [PubMed: 24493126]
- [136]. Drew SC, Masters CL, Barnham KJ. *PLoS One*. 2010; 5:e15875. [PubMed: 21209855]
- [137]. Atrian-Blasco E, Conte-Daban A, Hureau C. *Dalton Trans*. 2017 in press.

Scheme 1.

Toxic events in the framework of the amyloid cascade hypothesis: (over)-production of the amyloidogenic Aβ peptide, formation of oligomeric species and ROS production associated to the formation of metal-Aβ complexes.

	5	10	15	20	25	30	35	40
A β _{1-16/28/40/42}	DAEFR	HDSGY	EVHHQ	KL ^V FF	AEDVG	SN ^K GA	IIGLM	VGGV ^V IA
A β _{3-16/28/40/42}	EFR	HDSGY	EVHHQ	KL ^V FF	AEDVG	SN ^K GA	IIGLM	VGGV ^V IA
A β _{p3-16/28/40/42}	pEFR	HDSGY	EVHHQ	KL ^V FF	AEDVG	SN ^K GA	IIGLM	VGGV ^V IA
A β _{4-16/28/40/42}	FR	HDSGY	EVHHQ	KL ^V FF	AEDVG	SN ^K GA	IIGLM	VGGV ^V IA
A β _{11-16/28/40/42}			EVHHQ	KL ^V FF	AEDVG	SN ^K GA	IIGLM	VGGV ^V IA
A β _{p11-16/28/40/42}			pEVHHQ	KL ^V FF	AEDVG	SN ^K GA	IIGLM	VGGV ^V IA

Scheme 2.

Sequence of N-terminally truncated A β peptides discussed in the present review.

Scheme 3.

Catalytic production of ROS by Cu(A β), from dioxygen and ascorbate as reductant and some methods to detect the production of the various ROS by spectrophotometry.

Scheme 4.

Scheme of the A β peptide self-assembly process. Applicability range for the techniques used to monitor the different phases of the aggregation process.

Scheme 5.

Proposed coordination sites of Cu(II)-hAβ (A), Cu(II)-Aβ₃₋₁₆ (B), Cu(II)-Aβ_{p3-16} (C), Cu(II)-Aβ₄₋₁₆ (D) and Cu(II)-Aβ₁₁₋₁₆ (E).

Table 1

Spectroscopic parameters and conditional affinity of Cu(II) bound to a selection of A β peptides and ROS production of the corresponding complex.

peptide	spectroscopic signatures				affinity	ROS production ^[c]	refs
	EPR		UV-Vis or CD		^c K _a @ pH 7.4 (M ⁻¹)		
	g	A /(10·4 cm ⁻¹) ^[a]	λ (nm)	ε (M ⁻¹ cm ⁻¹)			
Aβ ₁₋₁₆	2.27 ± 0.01	183 ± 5	620	60	1.1 ± 0.1 10 ¹⁰	0.4	[34] and refs. therein
Aβ ₃₋₁₆	2.22 ± 0.01	160 ± 5	ND/ ^[b]	ND	3.3 ± 0.2 10 ⁹	0.2	[134]
Aβ ₄₋₁₆	2.18 ± 0.01	210 ± 5	525	100	3.4 ± 0.1 10 ¹³	not detected	[103, 105]
Aβ _{11-15/28}	2.17 ± 0.01	205 ± 5	520	90	3.0 ± 0.1 10 ¹³	ND	[104, 114]
Aβ _{p3-16}	2.26 ± 0.01	180 ± 5	ND	ND	8 ± 1 10 ⁷	0.12	[134, 136]

$^{[a]}$ $A_{\parallel}$ parameters refer to ^{63}Cu .

$^{[b]}$ ND = not determined.

$^{[c]}$ measured as rate of hydroxylation of CCA (in percentage of hydroxylation of CCA by Cu in buffer only). cK_a corresponds to the conditional affinity value, i.e. the absolute affinity value at a given pH value.